122 related articles for article (PubMed ID: 18639519)
1. Dominant antigenic peptides located at the heavy chain terminal of botulinum neurotoxin B contain receptor-binding sites for synaptotagmin II.
Shi J; Bao S; Yin J; Cai K; Hou X; Xiao L; Tu W; Wang Q; Wang H
Biochem Biophys Res Commun; 2008 Sep; 374(2):331-5. PubMed ID: 18639519
[TBL] [Abstract][Full Text] [Related]
2. Recombinant luminal domain of human synaptotagmin II in combination with gangliosides inhibits the toxicity of botulinum neurotoxins in mice.
Shi J; Li T; Hou X; Cai K; Bao S; Liu H; Gao X; Xiao L; Tu W; Wang Q; Yin J; Wang H
Microbes Infect; 2010 Apr; 12(4):319-23. PubMed ID: 20080203
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of cell surface receptor recognition by botulinum neurotoxin B.
Chai Q; Arndt JW; Dong M; Tepp WH; Johnson EA; Chapman ER; Stevens RC
Nature; 2006 Dec; 444(7122):1096-100. PubMed ID: 17167418
[TBL] [Abstract][Full Text] [Related]
4. A new neutralizing antibody against botulinum neurotoxin B recognizes the protein receptor binding sites for synaptotagmins II.
Wang H; Li T; Shi J; Cai K; Hou X; Wang Q; Xiao L; Tu W; Liu H; Gao X
Microbes Infect; 2010 Nov; 12(12-13):1012-8. PubMed ID: 20650331
[TBL] [Abstract][Full Text] [Related]
5. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity.
Jin R; Rummel A; Binz T; Brunger AT
Nature; 2006 Dec; 444(7122):1092-5. PubMed ID: 17167421
[TBL] [Abstract][Full Text] [Related]
6. Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E.
Mansour AA; Mousavi SL; Rasooli I; Nazarian S; Amani J; Farhadi N
Biologicals; 2010 Mar; 38(2):260-4. PubMed ID: 19879159
[TBL] [Abstract][Full Text] [Related]
7. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.
Atassi MZ; Oshima M
Crit Rev Immunol; 1999; 19(3):219-60. PubMed ID: 10422600
[TBL] [Abstract][Full Text] [Related]
8. Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity.
Strotmeier J; Willjes G; Binz T; Rummel A
FEBS Lett; 2012 Feb; 586(4):310-3. PubMed ID: 22265973
[TBL] [Abstract][Full Text] [Related]
9. Differential contribution of the residues in C-terminal half of the heavy chain of botulinum neurotoxin type B to its binding to the ganglioside GT1b and the synaptotagmin 2/GT1b complex.
Kohda T; Ihara H; Seto Y; Tsutsuki H; Mukamoto M; Kozaki S
Microb Pathog; 2007; 42(2-3):72-9. PubMed ID: 17188834
[TBL] [Abstract][Full Text] [Related]
10. Botulinum neurotoxin G binds synaptotagmin-II in a mode similar to that of serotype B: tyrosine 1186 and lysine 1191 cause its lower affinity.
Willjes G; Mahrhold S; Strotmeier J; Eichner T; Rummel A; Binz T
Biochemistry; 2013 Jun; 52(22):3930-8. PubMed ID: 23647335
[TBL] [Abstract][Full Text] [Related]
11. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
12. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
[TBL] [Abstract][Full Text] [Related]
13. The binding sites on botulinum neurotoxin B for synaptotagmin and for blocking antibodies.
Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
Biochem Biophys Res Commun; 2008 Nov; 376(3):631-2. PubMed ID: 18796292
[No Abstract] [Full Text] [Related]
14. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.
Peng L; Berntsson RP; Tepp WH; Pitkin RM; Johnson EA; Stenmark P; Dong M
J Cell Sci; 2012 Jul; 125(Pt 13):3233-42. PubMed ID: 22454523
[TBL] [Abstract][Full Text] [Related]
15. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
Zhou Y; Singh BR
Protein Expr Purif; 2004 Mar; 34(1):8-16. PubMed ID: 14766296
[TBL] [Abstract][Full Text] [Related]
16. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept.
Rummel A; Eichner T; Weil T; Karnath T; Gutcaits A; Mahrhold S; Sandhoff K; Proia RL; Acharya KR; Bigalke H; Binz T
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):359-64. PubMed ID: 17185412
[TBL] [Abstract][Full Text] [Related]
17. Production and characterization of a recombinant chimeric antigen consisting botulinum neurotoxin serotypes A, B and E binding subdomains.
Ebrahimi F; Rasaee MJ; Mousavi SL; Babaeipour V
J Toxicol Sci; 2010 Feb; 35(1):9-19. PubMed ID: 20118620
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.
Yang GH; Kim KS; Kim HW; Jeong ST; Huh GH; Kim JC; Jung HH
Toxicon; 2004 Jul; 44(1):19-25. PubMed ID: 15225558
[TBL] [Abstract][Full Text] [Related]
19. Location of the synaptosome-binding regions on botulinum neurotoxin B.
Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
Biochemistry; 2012 Jan; 51(1):316-28. PubMed ID: 22146011
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons.
Dong M; Tepp WH; Liu H; Johnson EA; Chapman ER
J Cell Biol; 2007 Dec; 179(7):1511-22. PubMed ID: 18158333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
